Takada, Hiroyuki published the artcileIdentification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells, COA of Formula: C12H17BO4S, the publication is Journal of Medicinal Chemistry (2019), 62(20), 9175-9187, database is CAplus and MEDLINE.
Dysferlinopathies, which are muscular diseases caused by mutations in the dysferlin gene, remain serious medical problems due to the lack of therapeutic agents. Herein, the authors report the design, synthesis, and structure-activity relations of a 2,6-disubstituted 3H-imidazo[4,5-b]pyridine series, which was identified from the phenotypic screening of chems. that increase the level of dysferlin in myocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs). Optimization studies with cell-based phenotypic assay led to the identification of a highly potent compound, 19, with dysferlin elevation effects at double-digit nanomolar concentrations In addition, the mol. target of the authors’ chem. series was identified as tubulin, through a tubulin polymerization assay and a competitive binding assay using a photoaffinity labeling probe.
Journal of Medicinal Chemistry published new progress about 1040281-86-4. 1040281-86-4 belongs to esters-buliding-blocks, auxiliary class Thiophene,Boronic acid and ester,Ester,Boronate Esters,Boronic Acids,Boronic acid and ester,Boronate Esters,, name is Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylate, and the molecular formula is C13H18BClO3, COA of Formula: C12H17BO4S.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics